Extended regimen feasible for ethinylestradiol/norelgestromin

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1499, 2005-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transdermal ethinylestradiol/norelgestromin comparable to an OC

Inpharma, Vol. 1, Iss. 1288, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Ethinylestradiol/norelgestromin: Myocardial infarction: case report

Reactions Weekly, Vol. 1, Iss. 1257, 2009-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Daclizumab + tacrolimus a feasible corticosteroid-free regimen

Inpharma, Vol. 1, Iss. 1480-1481, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Cycle Control and Bleeding Pattern of a 24/4 Regimen of Drospirenone 3 mg/Ethinylestradiol 20 μg Compared with a 21/7 Regimen of Desogestrel 150 μg/Ethinylestradiol 20 μg: A Pooled Analysis

By Anttila Leena

Clinical Drug Investigation, Vol. 31, Iss. 8, 2011-08 ,pp. : 519-525

Adis International

Access to resources Recommend Favorite

Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen): A Review of Its Use in Contraception, Premenstrual Dysphoric Disorder and Moderate Acne Vulgaris

By Fenton Caroline Wellington Keri Moen Marit D. Robinson Dean M.

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1749-1765

Adis International

Access to resources Recommend Favorite